Last reviewed 2026-04-19 · How we verify

LETEPRINIM

Phase 2 active Small molecule

LETEPRINIM is a drug. It is currently in Phase 2 development.

LETEPRINIM is a small molecule that works by binding to a specific target in the body to produce its therapeutic effect.

LETEPRINIM is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for LETEPRINIM are also unknown. Further information on its pharmacokinetics, such as half-life and bioavailability, is not available. As a result, key safety considerations and generic manufacturers are also unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	LETEPRINIM
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

In simple terms, LETEPRINIM is a small molecule that fits into a specific lock in the body, which helps to stop or slow down a particular process that is causing a disease or condition. This lock is a protein, and LETEPRINIM is designed to bind to it in a way that blocks its normal function. By doing so, LETEPRINIM can help to reduce symptoms or prevent the progression of a disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LETEPRINIM CI brief — competitive landscape report
LETEPRINIM updates RSS · CI watch RSS

Frequently asked questions about LETEPRINIM

What is LETEPRINIM?

LETEPRINIM is a Small molecule drug.

How does LETEPRINIM work?

LETEPRINIM is a small molecule that works by binding to a specific target in the body to produce its therapeutic effect.

What development phase is LETEPRINIM in?

LETEPRINIM is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing